Expected Revenue Growth: The clinical trial supplies market is projected to reach USD 2.5 billion by 2025 from USD 1.7 billion in 2020, at a CAGR of 7.8%. The increasing R&D expenditure in pharmaceutical and biopharmaceutical companies and the globalization of clinical trials & harmonization …
In the last few months, the number of patient visits to hospitals has reduced significantly, despite emergency and OPD services being available in hospitals. Before commencing any interventional procedure, surgeons run through a series of clinical tests to decide the best treatment for patients. However, …
Recent Developments in the Global Pharmaceutical Excipients Manufacturing Market: # In April 2019, Colorcon, Inc. (US) signed an agreement with DuPont Nutrition and Biosciences (US) in order to enhance the current product portfolio of CR Alliance products. # In February 2019, Associated British Foods plc (UK) signed …
Market growth is primarily driven by factors such as growing production of large molecules and biologics, technological advancements in nanofibers, growth in the generics market, and regulatory mandates for cleanrooms in pharmaceutical production. Other factors supporting market growth include an increase in R&D spending by …
Current Situation: COVID-19 Impact on Global Topical Drug Delivery Market According to our findings, the Topical Drug Delivery Procedure Market is expected to grow at an approximate CAGR of 6-7% during the next two years. According to our analysis, the below factors are playing a …
Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking …
Growth in this market is driven by the growing pharmaceutical industry in Latin American countries such as Brazil, Mexico, and Argentina; increasing focus of MNCs on investing in the pharmaceutical and healthcare sectors in Latin America; growing pricing pressures; rapid growth in aging population & …
Factors such as the growing prevalence of target diseases, the favorable reimbursement scenario in major markets, and advancements in technologies & designs of electronic drug delivery systems are driving the growth of the electronic drug delivery systems market during the forecast period. However, emerging economies …
Major Growth Boosting Factors: Market growth is largely driven by the global increase in the prevalence of chronic diseases. In addition, technological advancements in transdermal drug delivery systems are also expected to support market growth in the coming years. Expected Revenue Growth: The transdermal drug …
The benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026. The presence of a large geriatric and target patient population and the improving healthcare infrastructure …
The metagenomic sequencing market is estimated to grow at a CAGR of 17.0% to reach USD 2.3 billion by 2024 from USD 1.0 billion in 2019. Market growth is largely driven by factors such as the significant applications of metagenomics in various fields, the various …
This market is projected to reach USD 129.8 billion by 2025 from USD 95.2 billion in 2020, at a CAGR of 6.4% during the forecast period. The growth of this market is majorly driven by the high prevalence of skin and soft tissue infections, the …
The pharmaceutical excipients market is projected to reach USD 9.7 billion by 2025 from USD 6.9 billion in 2019, at a CAGR of 5.8%. Factors such as the growing pharmaceuticals industry coupled with advancements in functional excipients, rising adoption of orphan drugs, and increasing uptake …
The global market size is projected to reach USD 21.4 billion by 2025 from USD 11.1 billion in 2020, at a CAGR of 14.0% during the forecast period. Major Revenue Growth Boosters:Market growth is largely driven by the growing R&D expenditure in the pharmaceutical & …